HRT in women with diabetes - Review of the effects on glucose and lipid metabolism

Diabetes Research and Clinical Practice

Volumn 54, Issue 2, 2001, Pages 67-77

  Palin, S L ^a,b   Kumar, S ^a   Sturdee, D W ^a   Barnett, A H ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

Diabetes; Glucose; Hormone replacement therapy (HRT); Lipids

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; GESTAGEN; GLUCOSE; HORMONE; LIPID; MEDROXYPROGESTERONE; NORETHISTERONE; NORGESTREL; ORAL ANTIDIABETIC AGENT; TIBOLONE;

AGE; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES CONTROL; DIET THERAPY; DRUG EFFECT; ENDOMETRIUM CANCER; GLUCOSE METABOLISM; HORMONE SUBSTITUTION; HUMAN; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPID METABOLISM; MENOPAUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; REVIEW; SEX DIFFERENCE;

EID: 0034788716     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(01)00277-7     Document Type: Review

References (96)

1. Is hormone replacement therapy prescribed for post-menopausal diabetic women?
2. Prevalence and characteristics associated with use of hormone replacement therapy in Britain
3. Do women with diabetes receive hormone replacement therapy?
4. Use of hormone replacement therapy by post-menopausal women in the United States
5. Hormone replacement therapy and glucose metabolism
6. Hormone replacement therapy in women with diabetes mellitus: A survey of knowledge of risks and benefits
7. Effects of 'natural oestrogen' replacement therapy on menopausal symptoms and blood clotting
8. Cardiovascular risk in women: The cardiologist's perspective
9. The role of hormone replacement therapy in the prevention of post-menopausal heart disease
10. Estrogen and coronary heart disease in women
11. Hormone therapy to prevent disease and prolong life in post-menopausal women
12. Cardiovascular mortality and noncontraceptive use of estrogen in women: Results from the Lipid Research Clinics Program Follow-Up Study
13. Post-menopausal hormone therapy and mortality
14. Post-menopausal estrogen therapy is associated with reduced risk for coronary heart disease in women with non-insulin-dependant diabetes mellitus
15. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post-menopausal women
16. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis
17. Design of the Women's Health Initiative clinical trial and observational study
18. The MRC long-term randomised control trial of hormone replacement therapy: Background, design and objectives
19. Hormones and heart disease in women: Heart and estrogen/progestin replacement study in perspective
20. Hormone replacement therapy and endometrial cancer risk: A meta-analysis
21. Relations between bleeding pattern, endometrial biopsy and oestrogen treatment in post-menopausal women
22. Effects of hormone replacement therapy on endometrial histology in post-menopausal women
23. The endometrial response to sequential and continuous combined oestrogen-progestogen replacement therapy
24. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer
25. Hormone replacement therapy and risk of thromboembolism: A population based case-control study
26. Risk of venous thromboembolism in users of hormone replacement therapy
27. Prospective study of exogenous hormones and the risk of pulmonary embolism in women
28. Menopause and hormone replacement therapy
29. Oestrogen and progestogen hormone replacement therapy for perimenopausal and post-menopausal women: Weight and body fat distribution
30. Hormone replacement therapy and blood pressure in hypertensive women
31. Do clinicians prescribe HRT for hypertensive post-menopausal women?
32. Menstruation and control of diabetes
33. Perimenstrual symptoms in women with diabetes mellitus and the relationship to diabetic control
34. Self-reported changes in capillary glucose and insulin requirements during the menstrual cycle
35. Comparison of pharmacodynamic properties of various estrogen formulations
36. Effect of ovarian hormones on glucose metabolism in mouse soleus muscle
37. The effects of oestrogen and progesterone on insulin sensitivity in female rats
38. Mechanisms behind insulin resistance in rat skeletal muscle after oophorectomy and additional testosterone treatment
39. Some atherogenic concomitants of menopause: The Framingham Study
40. Menopause and risk factors for coronary heart disease
41. Ageing and the response of plasma insulin, glucose and C-peptide concentrations to intravenous glucose in post-menopausal women
42. A possible bimodal effect of estrogen on insulin sensitivity in post-menopausal women and the attenuating effect of added progestin
43. The effects of the menopause on insulin sensitivity, secretion and elimination in non-obese, healthy women
44. Effect of menopausal status on insulin-stimulated glucose disposal
45. Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in post-menopausal women with non insulin-dependant diabetes mellitus
46. Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in post-menopausal women with NIDDM
47. Lipoproteins and low-dose estradiol replacement therapy in post-menopausal type 2 diabetic patients: The effects of addition of norethisterone acetate
48. The effect of estrogen on intravenous glucose tolerance in women
49. Effect of hormone replacement therapy on glucose tolerance in post-menopausal women
50. Effect of post-menopausal hormone therapy on glucose and insulin concentrations
51. The effects of hormone replacement therapy on plasma lipids in type 2 diabetes
52. Effects of long-term estrogen replacement therapy
53. A prospective study of post-menopausal estrogen therapy and subsequent incidence of non-insulin-dependant diabetes mellitus
54. Post-menopausal estrogen replacement: A long-term cohort study
55. The effect of post-menopausal estrogen therapy on the risk of non-insulin-dependant diabetes mellitus
56. The effect of transdermal estrogen replacement therapy on hyperandrogenicity and glucose homeostasis in post-menopausal women with NIDDM
57. Effects of low doses of transdermal 17β-estradiol on carbohydrate metabolism in post-menopausal women
58. A comparison of the effects of oral and transdermal estrogen replacement on insulin sensitivity in post-menopausal women
59. The effect of estradiol and a combined estradiol/progestogen preparation on insulin sensitivity in healthy postmenopausal women
60. Recent and past use of conjugated estrogens in relation to adenocarcinoma of the endometrium
61. Risk of exogenous estrogen therapy and endometrial cancer
62. Exogenous estrogens and endometrial cancer: A case-control study and assessment of potential biases
63. Diabetes, body size and risk of endometrial cancer
64. Effects of natural oestrogen/progestogen substitution therapy on carbohydrate and lipid metabolism in post-menopausal women
65. Post-menopausal hormone replacement improves proteinuria and impaired creatinine clearance in type 2 diabetes mellitus and hypertension
66. Hormone replacement therapy with Kliofem in post-menopausal women with diabetes-metabolic effects after one year
67. Ischaemic heart disease risk in post-menopausal women
68. Lipid and lipoprotein responses to oral combined hormone replacement therapy in normolipaemic obese women with controlled type 2 diabetes mellitus
69. Effects of post-menopausal hormone replacement therapy on central abdominal fat, glycaemic control, lipid metabolism, and vascular factors in type 2 diabetes
70. Effects of percutaneous 17β-oestradiol and oral progesterone as replacement therapy of the post-menopause on blood pressure and metabolic parameters in non-insulin dependant diabetic women
71. The effect of transdermal HRT on insulin sensitivity in women with type 2 diabetes mellitus
72. Short term blood pressure and metabolic effects of tibolone in post-menopausal women with non-insulin dependant diabetes
73. Effects of menopause and estrogen replacement therapy or hormone replacement therapy in women with diabetes mellitus: Consensus opinion of The North American Menopause Society
74. Prevention of diabetes mellitus
75. Mortality and survival in type 2 (non-insulin-dependant) diabetes mellitus
76. Diabetes and cardiovascular risk factors: The Framingham Study
77. Sex differences in ischaemic heart disease mortality in diabetics
78. Why, as a woman interested in women's health and diabetes, I am not rushing to put my patients on HRT
79. Prior to use of estrogen replacement therapy, are users healthier than nonusers?
80. Menopause and risk factors for coronary heart disease
81. Post-menopausal estrogen use and heart disease risk factors in the 1980s
82. Effects of hormonal replacement on lipids and lipoproteins in post-menopausal women
83. Effects of post-menopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins
84. Associations of hormone replacement therapy with various cardiovascular risk factors for post-menopausal women
85. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in post-menopausal women
86. Hormone replacement therapy and cardiovascular risk in post-menopausal women with NIDDM
87. Role of insulin resistance in human disease
88. The effects of oestrogen replacement therapy on haemostatic variables in post-menopausal women with non-insulin dependant diabetes mellitus
89. Can post-menopausal hormone replacement improve plasma lipids in women with diabetes?
90. Lipoprotein (a)-Heterogeneity and biological relevance
91. The lowering of lipoprotein (a) induced by estrogen plus progesterone replacement therapy in post-menopausal women
92. The effect of estrogen replacement therapy with or without progestogen on the fibrinolytic system and coagulation inhibitors in post-menopausal status
93. Effect of 17β-estradiol on plasma lipids and LDL oxidation in post-menopausal women with type 2 diabetes mellitus